Controversias en hemostasia y trombosis / Controversy in haemostasia and thrombosis
Hematología (B. Aires)
; 5(1): 15-17, ene.-abr. 2001.
Article
in Spanish
| LILACS
| ID: lil-317817
Responsible library:
AR67.1
ABSTRACT
We should offer anticoagulation (INR 2-3) to patients with atrial fibrilation and valvular disease. We should also anticoagulate patients with high risk cardioembolic nonvalvular atrial fibralation like 1-Prior stroke, transient ischemic attack or peripheral embolia. 2-Diabetes. 3-Sistolic hypertension > 160 mmHg. 4- Recent heart failure. 5- Age > 75 years and female gender. We should not offer anticoagulant therapy to patients with lone atrial fibrilation and also to patients with low cardioembolic risk atrial fibrilation and high risk or bleeding like 1- prior gastrointestinal bleeding. 2- Hemorragic disease. 3-Prior compliance to anticoagulant treatment. 4- Cormobid severe disease. In this patients we may use aspirin 325 mg daily. Advanced age is not a contraindication to anticoagulation but it could justify more frequent blood test controls
Search on Google
Collection:
International databases
Database:
LILACS
Main subject:
Coronary Thrombosis
/
Hemostasis
Limits:
Humans
Language:
Spanish
Journal:
Hematología (B. Aires)
Journal subject:
Hematology
Year:
2001
Document type:
Article
Affiliation country:
Argentina
Institution/Affiliation country:
Hospital Británico de Buenos Aires/AR
/
Instituto de Investigaciones Hematológicas Mariano R. Castex/AR